EyePoint (EYPT) expects its cash, cash equivalents, and marketable securities as of June 30, 2025 will enable the Company to fund operations into 2027 beyond topline Phase 3 data for DURAVYU in wet AMD expected in 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EYPT:
- Buy Rating for EyePoint Pharmaceuticals: Duravyu’s Competitive Edge and Reliability Drive Investment Confidence
- Positive Buy Rating for EyePoint Pharmaceuticals Driven by Promising Clinical Trials and Market Valuation
- EyePoint’s wAMD study fully enrolled ahead of expectations, says RBC Capital
- EyePoint Completes Enrollment for Phase 3 Trials
- EyePoint completes enrollment of Phase 3 trials for DURAVYU in wet AMD